10x Genomics, Inc. TXG Income Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $642.82M+5.2% | $610.79M-1.3% | $618.73M+19.8% | $516.41M+5.3% | ||
| $198.94M+1.3% | $196.3M-6.3% | $209.41M+74.0% | $120.39M+62.5% | ||
| $443.88M+7.1% | $414.48M+1.3% | $409.31M+3.4% | $396.02M-4.9% | ||
| 69.1%+1.2pp | 67.9%+1.7pp | 66.2%-10.5pp | 76.7%-8.2pp | ||
| $238.63M-9.8% | $264.7M-2.1% | $270.33M+1.8% | $265.67M+25.5% | ||
| $316.13M-8.2% | $344.34M+0.3% | $343.33M+15.1% | $298.3M+15.8% | ||
| $504.87M-17.1% | $609.04M-9.7% | $674.64M+19.6% | $563.97M+20.3% | ||
| -$60.99M+68.7% | -$194.56M+26.7% | -$265.33M-58.0% | -$167.94M-221% | ||
| -9.5%+22.4pp | -31.9%+11.0pp | -42.9%-10.4pp | -32.5%-21.9pp | ||
| $21.08M+25.0% | $16.86M+1.8% | $16.57M+177% | $5.97M+509% | ||
| -$39.91M+77.5% | -$177.7M+28.6% | -$248.76M-53.6% | -$161.97M-202% | ||
| $3.64M-26.2% | $4.93M-22.2% | $6.34M+57.3% | $4.03M-10.6% | ||
| -$43.54M+76.2% | -$182.63M+28.4% | -$255.1M-53.7% | -$166M-185% | ||
| -6.8%+23.1pp | -29.9%+11.3pp | -41.2%-9.1pp | -32.1%-20.3pp | ||
| -$0.35+77.1% | -$1.53+29.5% | -$2.17-47.6% | -$1.47-177% | ||
| -$24.79M+84.4% | -$158.68M+31.0% | -$229.82M-61.2% | -$142.58M-358% | ||
| -3.9%+22.1pp | -26%+11.2pp | -37.1%-9.5pp | -27.6%-21.3pp | ||
| -$60.99M+68.7% | -$194.56M+26.7% | -$265.33M-58.0% | -$167.94M-221% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are 10x Genomics, Inc.'s profit margins?
- Gross margin is 69.6% and operating margin is -6.1%, with a -3.5% net margin.
- Where does 10x Genomics, Inc.'s income statement data come from?
- Every line is extracted from 10x Genomics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.